ORIGINAL ARTICLESGender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertralineThiels, Corneliaa; Linden, Michaelb; Grieger, Frankc; Leonard, JoachimdAuthor Information aDepartment of Social Sciences, University of Applied Sciences, Bielefeld bResearch Group Psychosomatic Rehabilitation, Charité University Hospital Benjamin Franklin, Berlin cInstitute for Research and Development, University of Witten-Herdecke, Witten-Herdecke dBoehringer Ingelheim Pharma KG, Ingelheim, Germany Correspondence and requests for reprints to Professor Dr M. Linden, Research Group Psychosomatic Rehabilitation, Charité, University Hospital Benjamin Franklin, Hindenburgdamm 30, Hs. IV, R. 528, 12200 Berlin, Germany Tel: +33 28 345678; fax: +33 28 345555; e-mail: email@example.com Received 15 April 2004 Accepted 17 September 2004 International Clinical Psychopharmacology: January 2005 - Volume 20 - Issue 1 - p 1-7 Buy Abstract Gender is known to have an influence on medical treatment and the prescribing and outcome of drug treatment. This has also been suggested for selective serotonin reuptake inhibitors (SSRIs). To examine sex differences in the treatment with the SSRI sertraline in routine treatment of depression, data from a 6-month prospective drug utilization observation study on 3858 women and 1594 men were analysed for gender differences. Compared to men, women were more often treated by a general practitioner, were somewhat older, had a later onset of illness, were more likely to suffer from a recurrent rather than a first episode of depression, had been treated for depression before, and showed more anxious and less neurasthenic or retarded syndromes. There was no difference regarding duration of the present episode or severity of illness. The mean prescribed dose of sertraline was marginally lower for females compared to males (45.5 versus 46.5 mg/day) with no difference in the rate of psychoactive concomitant medication (6.76% versus 6.80%). There was no difference in side-effects, treatment termination or treatment response. © 2005 Lippincott Williams & Wilkins, Inc.